Back

International survery confirms CardioQ-ODM's market leading position in intensive care units

14 September 2009 - Deltex Medical Group plc ("Deltex Medical" or "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces the results of a new survey into doctors' technology preferences for monitoring cardiac output in intensive care.

The survey was conducted by doctors from the University Hospital Ospedali Riunit, Foggia, Italy who contacted 112 international intensive care units of whom 65 responded. The survey confirmed the trend towards less invasive methods of monitoring cardiac output and, of these, ODM was the first choice of technology of 55% of respondents. The next most popular technology was the first choice of 24% of respondents.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"CardioQ-ODM has for several years been the market leading device for monitoring cardiac output in UK intensive care units, where there is wide recognition of its ease of use, safety and clinical utility in the hands of both doctors and nurses. This survey is highly encouraging that the benefits of CardioQ-ODM in intensive care medicine are now becoming widely recognised in export markets."

For further information, please contact:

Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman: njk@deltexmedical.com
Ewan Phillips, Chief Executive: eap@deltexmedical.com
Paul Mitchell, Finance Director: pjm@deltexmedical.com

Nominated Adviser and Broker
Arden Partners plc 020 7398 1600
Christopher Hardie: chris.hardie@arden-partners.com
Matthew Armitt: matthew.armitt@arden-partners.com

Kreab Gavin Anderson 020 7554 1400
Deborah Walter: dwalter@gavinanderson.co.uk
Robert Speed: rspeed@gavinanderson.co.uk